The role of the NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of duloxetine in the forced swimming test

Pharmacology Biochemistry and Behavior

Volumn 103, Issue 2, 2012, Pages 408-417

  Zomkowski, Andréa D E ^a   Engel, Daiane ^a   Cunha, Mauricio P ^a   Gabilan, Nelson H ^a   Rodrigues, Ana Lúcia S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Depression; Duloxetine; Forced swimming test; Nitric oxide; NMDA; Tail suspension test

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 7 NITROINDAZOLE; ARGININE; DEXTRO SERINE; DIZOCILPINE; DULOXETINE; GUANOSINE; METHYLENE BLUE; N ACETYL S NITROSOPENICILLAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; SILDENAFIL;

ANIMAL BEHAVIOR; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMOBILIZATION; LOCOMOTION; MONOAMINERGIC SYSTEM; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL;

ANIMALS; ANTIDEPRESSIVE AGENTS; ARGININE; CYCLIC GMP; FEMALE; MICE; NITRIC OXIDE; RECEPTORS, N-METHYL-D-ASPARTATE; SWIMMING; THIOPHENES;

EID: 84867317602     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2012.09.011     Document Type: Article

References (62)

1. R.C. Almeida, C.S. Felisbino, M.G. López, A.L.S. Rodrigues, and N.H. Gabilan Evidence for the involvement of l-arginine-nitric oxide cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice Behav Brain Res 168 2006 318 322
2. J. Angulo, P. Cuevas, B. Cuevas, S. Gupta, and I.S. Tejada Mechanisms for the inhibition of genital vascular responses by antidepressants in a female rabbit model J Pharmacol Exp Ther 310 2004 141 149
3. J.A. Beavo Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms Physiol Rev 75 1995 725 748
4. G.A. Bellingham, and P.W. Peng Duloxetine: a review of its pharmacology and use in chronic pain management Reg Anesth Pain Med 35 2010 294 303
5. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, and D.S. Charney Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 2000 351 354
6. R.W. Binfaré, A.O. Rosa, K.R. Lobato, A.R.S. Santos, and A.L.S. Rodrigues Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission Prog Neuropsychopharmacol Biol Psychiatry 33 2009 530 540
7. S.F. Bomholt, J.D. Mikkelsen, and G. Blackburn-Munro Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain Neuropharmacology 48 2005 252 263
8. J.M. Boyce-Rustay, and A. Holmes Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice Neuropsychopharmacology 31 2006 2405 2411
9. P.A. Boyer, P. Skolnick, and L.H. Fossom Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study J Mol Neurosci 10 1998 219 233
10. S.K. Brannan, C.H. Mallinckrodt, M.J. Detke, J.G. Watkin, and G.D. Tollefson Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies J Psychiatr Res 39 2005 161 172
11. P.S. Brocardo, J. Budni, K.R. Lobato, M.P. Kaster, and A.L.S. Rodrigues Antidepressant-like effect of folic acid: involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway Eur J Pharmacol 598 2008 37 42
12. N.J. Carter, and P.L. McCormack Duloxetine: a review of its use in the treatment of generalized anxiety disorder CNS Drugs 23 2009 523 541
13. L. Ciulla, H.S. Menezes, B.B. Bueno, A. Schuh, R.J. Alves, and M.P. Abegg Antidepressant behavioral effects of duloxetine and fluoxetine in the rat forced swimming test Acta Cir Bras 22 2007 351 354
14. J.F. Cryan, and D.A. Slattery Animal models of mood disorders: recent developments Curr Opin Psychiatry 20 2007 1 7
15. J.F. Cryan, A. Markou, and I. Lucki Assessing antidepressant activity in rodents: recent developments and future needs Trends Pharmacol Sci 23 2002 238 245
16. G. Da Silva, A. Matteussi, A.R.S. Santos, J.B. Calixto, and A.L.S. Rodrigues Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice Neuroreport 11 2000 3699 3702
17. M.J. Detke, C.G. Wiltse, C.H. Mallinckrodt, R.K. Mcnamara, M.A. Demitrack, and I. Bitter Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial Eur Neuropsychopharmacol 14 2004 457 470
18. A. Dhir, and S.K. Kulkarni Involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice Prog Neuropsychopharmacol Biol Psychiatry 31 2007 921 925
19. L. Eroglu, and B. Caglayan Anxiolytic and antidepressant properties of methylene blue in animal models Pharmacol Res 36 1997 381 385
20. J.V. Esplugues NO as a signalling molecule in the nervous system Br J Pharmacol 135 2002 1079 1095
21. M. Ghasemi, H. Sadeghipour, A. Mosleh, H.R. Sadeghipour, A.R. Mani, and A.R. Dehpour Nitric oxide involvement in the antidepressant-like of acute lithium effects administration in the mouse forced swimming test Eur Neuropsychopharmacol 18 2008 323 332
22. M. Ghasemi, L. Montaser-Kouhsari, H. Shafarodi, B.G. Nezami, F. Ebrahimi, and A.R. Dehpour NMDA/receptor nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test Psychopharmacology 206 2009 325 333
23. M. Ghasemi, M. Raza, and A.R. Dehpour NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test J Psychopharmacol 24 2010 585 594
24. A.J. Harkin, K.H. Bruce, B. Craft, and I.A. Paul Nitric oxide synthase inhibitors have antidepressant-like properties in mice. Acute treatments are active in the forced swim test Eur J Pharmacol 372 1999 207 213
25. A.J. Harkin, T.J. Connor, M. Walsh, N. St John, and J.P. Kelly Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors Neuropharmacology 44 2003 616 623
26. A. Harkin, T.J. Connor, M.P. Burns, and J.P. Kelly Nitric oxide inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test Eur Neuropsychopharmacol 14 2004 274 281
27. B.H. Harvey, L.P. Jonker, L. Brand, M. Heenop, and D.J. Stein NMDA receptor involvement in imipramine withdrawal associated effects on swim stress, GABA levels and NMDA receptor binding in rat hippocampus Life Sci 71 2002 43 54
28. A.J. Heiberg, G. Wegener, and R. Rosenberg Reduction of cGMP and nitric oxide has antidepressant like effects in the forced swimming test in rats Behav Brain Res 134 2002 479 484
29. J.M. Hevel, and M.A. Marletta Nitric-oxide synthase assays Methods Enzymol 233 1994 250 258
30. M.E. Hunziker, B.T. Suehs, T.L. Bettinger, and M.L. Crisrnon Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder Clin Ther 27 2005 1126 1143
31. D.C. Javitt, and S.R. Zukin Biexponential kinetics of [3H]MK-801 binding: evidence for access to closed and open N-methyl-D-aspartate receptor channels Mol Pharmacol 35 1989 387 393
32. S.R. Joca, and F.S. Guimarães Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects Psychopharmacology 185 2006 298 305
33. M.P. Kaster, P.K. Ferreira, A.R.S. Santos, and A.L.S. Rodrigues Effect of potassium channel inhibitors in the forced swimming test: possible involvement of l-arginine-nitric oxide-soluble guanylate cyclase pathway Behav Brain Res 165 2005 204 209
34. M.P. Kaster, A.O. Rosa, A.R.S. Santos, and A.L.S. Rodrigues Involvement of nitric oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test Int J Neuropsychopharmacol 8 2005 601 606
35. J.P. Kiss Role of nitric oxide in the regulation of monoaminergic neurotransmission Brain Res Bull 52 2000 459 466
36. M. Mantovani, R. Pertile, J.B. Calixto, A.R.S. Santos, and A.L.S. Rodrigues Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-D-aspartate receptors and the l-arginine-nitric oxide pathway Neurosci Lett 343 2003 1 4
37. M. Moretti, A.E. Freitas, J. Budni, S.C.P. Fernandes, G.O. Balen, and A.L.S. Rodrigues Involvement of nitric oxide-cGMP pathway in the antidepressant-like effect of ascorbic acid in the tail suspension test Behav Brain Res 225 2011 328 333
38. J.C. Owen, and P.S. Whitton Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats Br J Pharmacol 145 2005 587 592
39. E. Poleszak, P. Wlaź, A. Wróbel, M. Dybała, M. Sowa, and S. Fidecka Activation of the NMDA/glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effects in the forced swim test Pharmacol Rep 59 2007 595 600
40. E. Poleszak, P. Wlaź, B. Szewczyk, A. Wlaź, R. Kasperek, and A. Wróbel A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice J Neural Transm 118 2011 1535 1546
41. R.D. Porsolt, A. Bertin, and M. Jalfre Behavioral despair in mice: a primary screening test for antidepressants Arch Int Pharmacodyn Ther 229 1977 327 336
42. J.P. Rénéric, and I. Lucki Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test Psychopharmacology 136 1998 190 197
43. Z. Rogóz, G. Skuza, J. Maj, and W. Danysz Synergistic effects of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats Neuropharmacology 42 2002 1024 1030
44. A.O. Rosa, J. Lin, J.B. Calixto, A.R.S. Santos, A.R.S. Santos, and A.L.S. Rodrigues Involvement of NMDA receptors and l-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice Behav Brain Res 144 2003 87 93
45. G. Sanacora, C.A. Zarate, J.H. Krystal, and H.K. Manji Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders Nat Rev Drug Discov 7 2008 426 437
46. C. Shelton, R. Entsuah, S.K. Padmanabhan, and P.E. Vinall Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo Int Clin Psychopharmacol 20 2005 233 238
47. P. Skolnick Antidepressants for the new millennium Eur J Pharmacol 375 1999 31 40
48. J.C.E. Smith, and P.S. Whitton Nitric oxide modulates N-methyl-D-aspartate-evoked serotonin release in the raphe nuclei and frontal cortex of the freely moving rat Neurosci Lett 291 2000 5 8
49. D. Smith, C. Dempster, J. Glanville, N. Freemantle, and I. Anderson Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis Br J Psychiatry 180 2002 396 404
50. S.H. Snyder Nitric oxide: first in a new class of neurotransmitters Science 257 1992 494 496
51. S.M. Stahl, M.M. Grady, C. Moret, and M. Briley SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants CNS Spectr 10 2005 732 747
52. L. Steru, R. Chermat, B. Thierry, and P. Simon The tail suspension test: a new method for screening antidepressants in mice Psychopharmacology 85 1985 367 370
53. E. Suzuki, G. Yagi, T. Nakaki, S. Kamba, and M. Asai Elevated plasma nitrate levels in depressive states J Affect Disord 63 2001 221 224
54. B.K. Szasz, A. Mike, R. Karoly, Z. Gerevich, P. Illes, and E.S. Vizi Direct inhibitory effect of fluoxetine on N-methyl-D-aspartate receptors in the central nervous system Biol Psychiatry 62 2007 1303 1309
55. M.E. Thase, A.R. Entsuah, and R.L. Rudolph Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors Br J Psychiatry 178 2001 234 241
56. M.E. Thase, Y.L. Pritchett, M.J. Ossanna, R.W. Swindle, J. Xu, and M.J. Detke Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder J Clin Psychopharmacol 27 2007 672 776
57. V. Volke, G. Wegener, M. Bourin, and E. Vasar Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2- trifluoromethylphenyl)-imidazole in mice Behav Brain Res 140 2003 141 147
58. G. Wegener, V. Volke, and R. Rosenberg Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo Br J Pharmacol 130 2000 575 580
59. M. Wong, and J. Licinio Research and treatment approaches to depression Nat Rev Neurosci 2 2001 343 351
60. F. Yildiz, B.F. Erden, G. Ulak, T. Utkan, and N. Gacar Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats Psychopharmacology 149 2000 41 44
61. C.A. Zarate, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 2006 856 864
62. A.D.E. Zomkowski, D. Engel, N.H. Gabilan, and A.L.S. Rodrigues Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test Eur Neuropsychopharmacol 20 2010 793 801